Equities research analysts at HC Wainwright lowered their Q4 2025 earnings estimates for Neurocrine Biosciences in a report issued on Friday, February 21st. HC Wainwright analyst A. Fein now expects ...
Over the last 7 days, the United States market has dropped 2.2%, yet it remains up by 18% over the past year with earnings expected to grow by 14% per annum in the coming years. In this context, ...
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.